Narrow Therapeutic Index- valproic acid and derivatives [Regulatives / Guidelines]

posted by MaggieSantos – Portugal, 2017-04-26 20:20 (2844 d 12:43 ago) – Posting: # 17271
Views: 3,309

Dear colleagues,

Concerning valproic acid and derivatives is not consentaneous that it should be considered as a narrow therapeutic índex for bioequivalence purposes. I know that for FDA it is a NTI. Do you have information for EMA, for individual European countries and for other countries around the World.

Depending on the submission country, the BE interval will differ.
Please, feel free to comment.

I need the more information I can get.

Kind Regards

MaggieSantos

Complete thread:

UA Flag
Activity
 Admin contact
23,376 posts in 4,912 threads, 1,667 registered users;
143 visitors (0 registered, 143 guests [including 5 identified bots]).
Forum time: 08:04 CET (Europe/Vienna)

The great tragedy of Science – the slaying
of a beautiful hypothesis by an ugly fact.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5